PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication
- PDF / 783,980 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 1 Downloads / 194 Views
ORIGINAL ARTICLE—LIVER, PANCREAS, AND BILIARY TRACT
PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication Daiki Miki1,2 • Tomoyuki Akita3 • Akemi Kurisu3 • Tomokazu Kawaoka1,2 • Tomoaki Nakajima4 • Shuhei Hige4 • Yoshiyasu Karino4 • Hidenori Toyoda5 • Takashi Kumada5 • Masataka Tsuge1,2 • Akira Hiramatsu1,2 • Michio Imamura1,2 Hiroshi Aikata1,2 • Clair Nelson Hayes1,2,8 • Koichi Honda6 • Masataka Seike6 • Norio Akuta7 • Mariko Kobayashi7 • Hiromitsu Kumada7 • Junko Tanaka2,3 • Kazuaki Chayama1,2,8
•
Received: 31 July 2020 / Accepted: 13 September 2020 Ó Japanese Society of Gastroenterology 2020
1
Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan
2
Research Center for Hepatology and Gastroenterology, Hiroshima University, Hiroshima, Japan
within 1 year and whose follow-up period was less than 1 year and who were positive for HBsAg, we investigated the association between clinical characteristics and HCC development after SVR in the remaining 3771 patients. Results Median observation period was 41 months. We confirmed known risk factors. In addition, we found that PNPLA3 and HLA-DQB1 polymorphisms were associated with HCC after SVR. Finally, we propose an estimation model for the incidence of HCC after SVR. Based on gender, FIB-4 index, AFP, and PNPLA3 polymorphism, about 18% of all patients were classified as having high risk, with a cumulative incidence rate (CIR) at 5 years of 16.5%. Another 17% were classified as having moderate risk with a CIR of 7.6%. The remaining 65% showed a CIR of 0.5%. The effect of PNPLA3 polymorphism might be more pronounced in patients with lower body mass index (BMI) and without diabetes mellitus compared to those with higher BMI and diabetes mellitus. Conclusions We demonstrated that PNPLA3 and HLADQB1 polymorphisms were associated with HCC after SVR. These findings might be useful to inform risk stratification for HCC surveillance after SVR.
3
Department of Epidemiology, Infectious Disease Control, and Prevention, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima, Japan
Keywords Hepatocellular carcinoma Hepatitis C Genomics Epidemiology
Abstract Background Even though both interferon (IFN)-based and direct-acting antiviral (DAA) therapies against hepatitis C virus (HCV) reduce the risk of hepatocellular carcinoma (HCC), post-sustained virological response (SVR) patients remain at elevated risk of HCC. Methods A total of 4620 patients who achieved SVR were enrolled in this retrospective cohort study. After excluding patients who had a history of HCC or developed HCC
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00535-020-01731-6) contains supplementary material, which is available to authorized users. & Kazuaki Chayama [email protected]
4
Department of Gastroenterology, Sapporo Kosei General Hospital, Sa
Data Loading...
